Waldencast plc Dossier - Source-backed chat

Waldencast plc

WALDNASDAQ

SectorConsumer Staples

IndustryPersonal Care Products

Beta (adjusted)0.29

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.86Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $109.3M

Enterprise Value $215.5M

Shares Outstanding 114.1M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Waldencast plc is undergoing a massive corporate transformation. On June 1, 2026, the company announced a definitive agreement to sell its Obagi Medical segment to Bridgepoint for up to $460 million. This transaction is highly strategic as it will completely wipe out the company's outstanding $178 million senior secured term loan facility, resolving the heavy debt load that has severely depressed equity value. Post-transaction, Waldencast will pivot to become a pure-play operator focused entirely on expanding and scaling the high-growth Milk Makeup cosmetics brand globally. While the balance sheet deleveraging is a major positive catalyst, a 'Hold' rating is maintained until the transaction officially closes, the leadership transition is finalized (with founders Michel Brousset and Hind Sebti departing to lead Obagi, and Felipe Dutra stepping in as Executive Chairman), and Milk Makeup demonstrates sustainable standalone profitability and international recovery.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.60

Mean target$2.28

High · most bullish analyst$3.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The Obagi divestiture faces unexpected regulatory or execution delays, or the final transaction adjustments significantly reduce the net cash proceeds. Standalone Milk Makeup struggles to achieve profitability due to high marketing requirements, intense competition in the prestige cosmetics space, and persistent international weakness, leaving the company with limited scale.

Base CaseCentral scenario

The sale of Obagi Medical successfully closes, delivering $366 million in upfront cash which is immediately used to pay off the $178 million senior secured term loan. Waldencast eliminates its heavy interest expense headwinds and operates with a clean balance sheet. Milk Makeup, under the leadership of President Mazdack Rassi, stabilizes its international distribution and maintains steady double-digit growth in the US, leading to a gradual re-rating of the stock as a high-growth, pure-play cosmetics brand.

Bull CaseUpside scenario

The successful closing of the Obagi Medical sale in Q3 2026 completely eliminates Waldencast's $178 million senior secured debt, leaving the company with a clean balance sheet and significant cash to aggressively scale Milk Makeup globally. Milk Makeup captures strong Gen Z demand and expands its international footprint, driving the company to standalone profitability and a significant upward re-rating of its valuation multiples.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Complete balance sheet transformation: The up to $460 million Obagi sale ($366 million upfront cash) will fully eradicate the $178 million senior secured term loan, removing a major overhang on the equity.
Pure-play focus: Transitioning to a single-brand focus on Milk Makeup simplifies the corporate structure, reduces operational complexity, and allows targeted capital allocation toward a high-growth consumer brand.
Strong US brand equity: Milk Makeup continues to deliver robust consumption growth in the US market, supported by strong retail partnerships with Sephora and Ulta.

Key Investment Risks

Execution and transition risk: The departure of co-founders Michel Brousset and Hind Sebti to lead Obagi leaves Waldencast with a major leadership transition under Executive Chairman Felipe Dutra.
Single-brand concentration: Post-divestiture, Waldencast's financial performance will be entirely dependent on Milk Makeup, increasing volatility and vulnerability to cosmetics industry trends.
International softness: Milk Makeup has experienced persistent international weakness, which could drag down overall growth if turnaround efforts fail.

Thesis Invalidation Triggers

Termination or material downward renegotiation of the Obagi Medical sale agreement with Bridgepoint.
Failure to fully repay the senior secured term loan or emergence of new high-interest liabilities.
A severe drop in Milk Makeup's US retail consumption or key distributor relationships (e.g., Sephora).

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.